Citigroup Maintains Buy on GoodRx Holdings, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Daniel Grosslight maintains a Buy rating on GoodRx Holdings (NASDAQ:GDRX) but lowers the price target from $11 to $10.

August 09, 2024 | 10:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup analyst Daniel Grosslight maintains a Buy rating on GoodRx Holdings but lowers the price target from $11 to $10.
The Buy rating suggests continued confidence in GoodRx Holdings, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100